100s of titles, one news app for just $10 a month.
Dive Deeper:
AbbVie's Upadacitinib Shows Clinical Response In Crohn's Disease Maintenance Study At One Year
AbbVie Inc (NYSE:ABBV) announced topline results from U-ENDURE Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease.…
Arcellx Doses First Patient in Phase 1 study of ACLX-001 in Relapsed or Refractory Multiple Myeloma
Arcellx, Inc. (NASDAQ: ACLX) announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical…
MediWound Posts Promising EscharEx Data For Chronic Wounds
MediWound Ltd (NASDAQ: MDWD) has announced results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous…
Praxis' PRAX-944 Shows Promising Action In Essential Tremor Patients
Praxis Precision Medicines Inc (NASDAQ:PRAX) announced topline results from Part B of its Phase 2a study evaluating the safety and efficacy of PRAX-944…
One subscription that gives you access to news from hundreds of sites
ACHV: First Quarter 2022 Results
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT
Lipocine Posts Encouraging Data For Testosterone Prodrug In NASH Patients
Lipocine Inc (NASDAQ:LPCN) has announced topline results from its Open-Label Extension (OLE) study of LPCN 1144, including an orally delivered prodrug of testosterone.…
Get all your news in one place
Latest Technology news:
Era of ‘tech exceptionalism’ must end: eSafety Commissioner
Australian eSafety Commissioner Julie Inman Grant has called on global regulators to end the “era of technological exceptionalism” and to…
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
Leno Tells Ford CEO He's A "Truck Guy" After Driving F-150 Lightning
Watch an interesting discussion between Jay Leno and Ford CEO Jim Farley as the famous car collector is introduced to…
ICE ally Trust Stamp just fixed a massive security flaw
Names and driver’s license information for a few dozen people have been wrongly released.
Snap Stock Dives, Drags Down Peers, On Big Warning Over Economy
Snap stock plunged late Monday after saying the macroeconomic environment has deteriorated further and faster than anticipated.
Tesla Model Y Performance Owner Lists 10 Things He Hates About It
The Model Y Performance is a great electric vehicle, but it could become even better with several improvements, most of…
From analysis to good news, read the world’s best news in one place
To Use Rather than Collect, the Second Coming of NFTs
NFTs have been called everything from fads to outright scams, but early adopters see a future for them as uniquely…
Clearview AI cops $13m fine in the UK, with help from Australia
Controversial facial recognition firm Clearview AI has been handed a $13.3 million fine by the UK privacy watchdog following a…

Protara Therapeutics Shares Retrospective Analysis Of OK-432 In Rare Lymphatic Malformations

By Vandana Singh
  • Protara Therapeutics Inc (NASDAQ:TARAannounced the results of a retrospective analysis of OK-432, the originator compound for TARA-002, its investigational therapy in development for lymphatic malformations (LMs), rare, congenital malformations of lymphatic vessels. 
  • The results from the analysis showed that OK-432 was clinically successful and generally well-tolerated in the treatment of both macrocystic and mixed-cystic LMs.
  • The retrospective analysis included 246 patients from a Phase 2 randomized study and 275 patients from an open-label study. 
  • In October, the FDA signed off Protara's Phase 1 trial of TARA-002 in adults with high-grade non-muscle invasive bladder cancer.
  • Approximately 69% of patients achieved clinical success in the immediate treatment group after six months, while only 7.5% of patients in the delayed treatment group showed spontaneous resolution.
  • 73.1% of patients in the open-label study achieved clinical success.
  • Patients were followed for up to three years post-treatment with no significant safety concerns.
  • Price Action: TARA shares are up 1.43% at $2.84 during the market session on the last check Thursday.
What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.

Dive Deeper:
AbbVie's Upadacitinib Shows Clinical Response In Crohn's Disease Maintenance Study At One Year
AbbVie Inc (NYSE:ABBV) announced topline results from U-ENDURE Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease.…
Arcellx Doses First Patient in Phase 1 study of ACLX-001 in Relapsed or Refractory Multiple Myeloma
Arcellx, Inc. (NASDAQ: ACLX) announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical…
MediWound Posts Promising EscharEx Data For Chronic Wounds
MediWound Ltd (NASDAQ: MDWD) has announced results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous…
Praxis' PRAX-944 Shows Promising Action In Essential Tremor Patients
Praxis Precision Medicines Inc (NASDAQ:PRAX) announced topline results from Part B of its Phase 2a study evaluating the safety and efficacy of PRAX-944…
One subscription that gives you access to news from hundreds of sites
ACHV: First Quarter 2022 Results
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT
Lipocine Posts Encouraging Data For Testosterone Prodrug In NASH Patients
Lipocine Inc (NASDAQ:LPCN) has announced topline results from its Open-Label Extension (OLE) study of LPCN 1144, including an orally delivered prodrug of testosterone.…
Get all your news in one place